NCT07244419 Prevention of Graft Rejection in Hematopoietic Stem Cell Transplant (HSCT) Recipients
| NCT ID | NCT07244419 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | Children's Hospital Medical Center, Cincinnati |
| Condition | Hematopoietic Stem Cell Transplantation |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2026-01-07 |
| Primary Completion | 2029-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 20 participants in total. It began in 2026-01-07 with a primary completion date of 2029-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The investigators hypothesize that graft rejection after hematopoietic stem cell transplant (HSCT) is primarily driven by interferon gamma, and prophylactic interferon gamma inhibition in high-risk patients will prevent graft rejection. Additionally, knowledge of emapalumab PK/PD and in vitro mechanistic effects of emapalumab in this novel setting will guide optimization of dosing regimens and treatment approaches in future studies.
Eligibility Criteria
Inclusion Criteria: * All patients undergoing allogeneic HSCT at our institution will be evaluated for graft rejection risk factors. Patients deemed high risk for graft rejection will have 2 or more of the following: mismatched or haploidentical donor, ex vivo t-cell depleted graft, prior history of graft rejection. Exclusion Criteria: * Known hypersensitivity to any constituent of the study medication.
Contact & Investigator
Anthony Sabulski, MD
PRINCIPAL INVESTIGATOR
Children's Hospital Medical Center, Cincinnati
Frequently Asked Questions
Who can join the NCT07244419 clinical trial?
This trial is open to participants of all sexes, studying Hematopoietic Stem Cell Transplantation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07244419 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07244419 currently recruiting?
Yes, NCT07244419 is actively recruiting participants. Contact the research team at Jessica.Anderson@cchmc.org for enrollment information.
Where is the NCT07244419 trial being conducted?
This trial is being conducted at Cincinnati, United States.
Who is sponsoring the NCT07244419 clinical trial?
NCT07244419 is sponsored by Children's Hospital Medical Center, Cincinnati. The principal investigator is Anthony Sabulski, MD at Children's Hospital Medical Center, Cincinnati. The trial plans to enroll 20 participants.